Jeffrey Graybill
Jeffrey Graybill is Vice President, CMC Commercial Strategy at Immatics, where he leads Operations and Manufacturing readiness activities supporting the planned launch of anzu-cel, Immatics' Phase 3 TCR-T therapy for melanoma.
Prior to joining Immatics, Jeff held cross-functional CMC Operations leadership roles at Bristol Myers Squibb, supporting the global launch and lifecycle management of Breyanzi®, the company's first CAR-T cell therapy. Earlier in his career, he held Supply Chain and Operations positions at Amgen, with responsibilities spanning clinical supply chain, project management, and medical device development.
Jeff holds a Master of Bioscience degree from Keck Graduate Institute and a Bachelor of Science in Bioengineering from Louisiana State University.